Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in angiodysplasia-related anemia
NCT02384122Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2015
- Primary completion
- Jul 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal angiodysplasia (GIAD) and anemia comparing Octreotide with Standard of Care (2 arms). Primary endpoint: Difference in blood and parenteral iron requirements at 52 weeks. Started Sep 2015; status: completed.
02
Drugs
octreotide
03
Conditions
gastrointestinal angiodysplasia (GIAD)anemia
Beyond the preview
Go deeper on NCT02384122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384122.